Sign in

    Edward Thomason • Kempen & Co

    Edward Thomason's questions to Verona Pharma PLC (VRNA) leadership

    Edward Thomason's questions to Verona Pharma PLC (VRNA) leadership • Q3 2024

    Question

    Edward Thomason asked for details on the specialty pharmacy inventory build and its contribution to Q3 sales. He also inquired about the importance of a new patent application for COPD exacerbations and whether any patients from the ENHANCE trial converted to commercial use.

    Answer

    Chief Financial Officer Mark Hahn estimated that inventory build, based on a 2-3 week supply held by partners, accounted for roughly a quarter of Q3 sales. Executive David Zaccardelli described the new patent filings as critically important to their overall IP estate. He also clarified there was no direct patient rollover from the ENHANCE trial to commercial supply due to the significant time gap.

    Ask Fintool Equity Research AI

    Edward Thomason's questions to Verona Pharma PLC (VRNA) leadership • Q2 2024

    Question

    Edward Thomason questioned the implications of Ohtuvayre's pricing on reimbursement, referencing recent news on cost-effectiveness. He also asked for a preview of the data expected at the upcoming ERS and CHEST medical conferences.

    Answer

    Chief Commercial Officer Chris Martin defended the WACC price of $22,950 as appropriate value, supported by pharmacoeconomic analyses, and stated they have seen no indication from payers that price will hinder coverage, especially under the medical benefit model. An unnamed executive previewed upcoming data presentations, which will include analyses on European populations, cough and sputum data, exacerbation effects by COPD phenotype, and analyses by smoking status and disease severity.

    Ask Fintool Equity Research AI